Idorsia Ltd stock analysis
Idorsia Ltd (0RQE) Share Price & Analysis
0RQE Stock Chart & Stats
- Day’s Range
- CHF 3.87 - CHF 3.95
- 52-Week Range
- CHF 2.82 - CHF 7.55
- Previous Close
- CHF 3.87
- Volume
- N/A
- Average Volume (3M)
- 65.58K
- Market Cap
- CHF 1.06B
- Enterprise Value
- CHF 2.51B
- Total Cash (Recent Filing)
- CHF 85.10M
- Total Debt (Recent Filing)
- CHF 1.35B
- Price to Earnings (P/E)
- ―
- Beta
- 1.29
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.18
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Improving TTM revenue indicates that Idorsia is generating stronger commercial activity across its portfolio. If sustained, this growth can broaden the revenue base, improve absorption of fixed operating costs, and support greater financial contribution from existing and newly launched medicines.
High Gross Margin
The consistently high gross margin shows that Idorsia’s products can generate substantial value after direct costs. This provides economic capacity to fund research, commercialization, and partnering activity, although the benefit depends on reducing the much larger operating-cost burden.
Diversified Commercial Model
Combining direct product revenue with licensing, milestone, and royalty income gives Idorsia multiple ways to monetize its drug portfolio. This model can extend commercial reach through larger partners while preserving selected product economics and creating potential recurring royalty streams.
Bears Say
Negative Equity And High Leverage
Negative equity and debt materially above the company’s asset base indicate weak balance-sheet resilience. This limits financial flexibility, increases dependence on creditors or external funding, and can constrain Idorsia’s ability to invest consistently in its pipeline or absorb setbacks.
Persistent Cash Burn
Continuing negative operating and free cash flow means the business is not yet funding itself through operations. Although outflows improved versus 2022–2023, ongoing cash burn keeps funding risk elevated and may require additional financing before durable cash generation is achieved.
Deep Operating Losses
The very negative net margin and continued EBIT and EBITDA losses show that the current cost base remains far above revenue. This weak operating leverage reduces the immediate benefit of high gross margins and makes earnings recovery dependent on sustained growth and meaningful cost improvement.
Idorsia Ltd News
0RQE FAQ
What was Idorsia Ltd’s price range in the past 12 months?
What is Idorsia Ltd’s market cap?
When is Idorsia Ltd’s upcoming earnings report date?
How were Idorsia Ltd’s earnings last quarter?
Is Idorsia Ltd overvalued?
Does Idorsia Ltd pay dividends?
What is Idorsia Ltd’s EPS estimate?
How many shares outstanding does Idorsia Ltd have?
What happened to Idorsia Ltd’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Idorsia Ltd?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Roland Wandeler
- Employees
- 456
- Website
- www.idorsia.com
- Address
- Hegenheimermattweg 91, Allschwil, BL, 4123, CH
Idorsia Ltd (0RQE) Earnings & Revenues
0RQE Earnings Call
Earnings Call SentimentPositive
The call communicated a clear operational turnaround: materially stronger commercial traction (QUVIVIQ sales > doubled, EUCAN strength), significant cost savings, improved operating losses and strengthened liquidity. These positives are balanced by remaining profitability gaps, U.S. access/regulatory uncertainty for QUVIVIQ (descheduling pending), an unfinished TRYVIO commercialization partnership process, and multi‑year timelines for key pipeline readouts (e.g., lucerastat). On balance, the company presented meaningful progress and a credible path to further de‑risking and growth, while acknowledging key near‑term risks tied to partnerships, U.S. regulatory outcomes and cash runway beyond the next inflection points.
View all GB:0RQE earnings summaries0RQE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |












